经颈动脉入路使用Evolut自膨胀瓣膜行TAVR的真实世界注册研究结果
基于STS/ACC TVT注册研究,纳入2015至2024年经颈动脉入路使用Evolut瓣膜行原生TAVR的2105例患者,平均年龄78.3岁,STS预测死亡风险6.4%。结果显示植入成功率99.6%,住院、30天和1年全因死亡率分别为2.1%、3.8%和16.5%,卒中发生率分别为3.1%、3.8%和5.1%,1年KCCQ评分平均改善30.5分。结论认为经颈动脉TAVR对髂股解剖不适患者安全有效。
要点
- 经颈动脉TAVR使用Evolut瓣膜植入成功率99.6%,住院死亡率2.1%。
- 30天卒中发生率3.8%,大血管并发症仅1.9%。
- 1年全因死亡率16.5%,KCCQ评分平均改善30.5分。
核心结论
- 经颈动脉入路使用Evolut自膨胀瓣膜行TAVR对髂股解剖不适患者是有效、安全的方法。
- 心脏团队应熟练掌握该技术以覆盖不同解剖条件的患者。
研究设计与样本
- 共纳入2105例患者,平均年龄78.3±7.9岁,平均STS预测死亡风险6.4±5.3%。
主要发现
- 植入成功率99.6%,95.8%使用全身麻醉,中位手术时间88.0分钟(Q1=68.0,Q3=115.0)。
- 中位住院时间2.0天(Q1=1.0,Q3=3.0),89.0%出院回家。
- 住院、30天和1年全因死亡率分别为2.1%、3.8%和16.5%。
- 住院、30天和1年卒中发生率分别为3.1%、3.8%和5.1%。
- 30天时大血管并发症1.9%,瓣膜相关再入院0.4%,非瓣膜相关再入院10.9%;1年KCCQ评分平均改善30.5±27.1分。
临床怎么用
- 对于髂股解剖不适的TAVR患者,经颈动脉入路使用Evolut瓣膜可作为替代选择。
- 心脏团队应熟悉经颈动脉技术以优化不同解剖谱系患者的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcarotid access for transcatheter aortic valve replacement (TAVR) is the most commonly used alternate access in the United States. Real-world evidence on transcarotid access using the Evolut self-expanding valve based on larger numbers of patients may help inform treatment optimization towards better outcomes. METHODS: The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry™ was queried for patients undergoing native TAVR using transcarotid access with an Evolut (January 2015-December 2024). In-hospital, 30-day, and 1-year outcomes are reported. RESULTS: We identified 2,105 patients (mean age 78.3±7.9 years) with mean Society of Thoracic Surgeons predicted risk of mortality 6.4±5.3. Most were high/extreme surgical risk (60.0%) with New York Heart Association class III/IV heart failure symptoms (66.8%) and mean baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) Score 45.3±25.4. Implant success was 99.6% primarily using general anesthesia (95.8%) with median procedure time of 88.0 (Q1=68.0, Q3=115.0) minutes. Median length of stay was 2.0 (Q1=1.0, Q3=3.0) days; 89.0% were discharged to home. In-hospital, 30-day and 1-year all-cause mortality was 2.1%, 3.8% and 16.5%; stroke occurred in 3.1%, 3.8% and 5.1% of patients, respectively. At 30 days, major vascular complications (1.9%), valve related (0.4%) and non-valve related (10.9%) readmissions were low. The mean change in KCCQ score from baseline to 1-year was +30.5±27.1 points. CONCLUSIONS: Transcarotid TAVR with the Evolut TAV is an effective, safe approach for patients with unfavorable iliofemoral anatomy. Heart teams should become facile with this technique to provide optimal care across the anatomy spectrum.
引用
- Allen KB, Huded C, Cohen DJ, et al. Transcarotid Access for Transcatheter Aortic Valve Replacement With the Evolut Self-Expanding Valve: Outcomes from a Real-World Registry. Ann Thorac Surg. 2026. PMID: 42887713. doi:10.1016/j.athoracsur.2026.09.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。